BOSTON — In this video from the National Kidney Foundation Spring Clinical Meetings, Joseph A. Vassalotti, MD, reviews results from late-breaking clinical trials.
Three abstracts were presented:
“In Matt Weir’s presentation, he talked about the use of patiromer to enable RAAS [renin-angiotensin-aldosterone system] blockade in patients with heart failure and reduced ejection fraction,” Vassalotti told Healio. “While patiromer is FDA approved, Matt highlighted some important features, particularly patients who are most likely to benefit from RAAS therapy are also the